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The integrity of epithelial and endothelial barriers in the lower airspaces of the lungs has
to be tightly regulated, in order to prevent leakage and to assure efficient gas exchange
between the alveoli and capillaries. Both G− and G+ bacterial toxins, such as lipopolysac-
charide and pneumolysin, respectively, can be released in high concentrations within the
pulmonary compartments upon antibiotic treatment of patients suffering from acute res-
piratory distress syndrome (ARDS) or severe pneumonia. These toxins are able to impair
endothelial barrier function, either directly, or indirectly, by induction of pro-inflammatory
mediators and neutrophil sequestration. Toxin-induced endothelial hyperpermeability can
involve myosin light chain phosphorylation and/or microtubule rearrangement. Endothe-
lial nitric oxide synthase (eNOS) was proposed to be a guardian of basal barrier function,
since eNOS knock-out mice display an impaired expression of inter-endothelial junction
proteins and as such an increased vascular permeability, as compared to wild type mice.
The enzyme arginase, the activity of which can be regulated by the redox status of the
cell, exists in two isoforms – arginase 1 (cytosolic) and arginase 2 (mitochondrial) – both of
which can be expressed in lung microvascular endothelial cells. Upon activation, arginase
competes with eNOS for the substrate L-arginine, as such impairing eNOS-dependent NO
generation and promoting reactive oxygen species generation by the enzyme. This mini-
review will discuss recent findings regarding the interaction between bacterial toxins and
arginase during acute lung injury and will as such address the role of arginase in bacterial
toxin-induced pulmonary endothelial barrier dysfunction.
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INTRODUCTION
Cells require energy to carry out their vital functions. Mitochondr-
ial oxidative phosphorylation is the main pathway through which
cellular ATP is generated, provided that an adequate and con-
tinuous amount of O2 is supplied to the mitochondria. This is
orchestrated by the microcirculation, which represents the inter-
face between the parenchymal cells in the tissues (the consumers)
and the circulatory system (the supplier).
In order for gas exchange between the 223 alveoli and the lung
capillaries in an adult human lung to occur in an optimal manner,
the alveolar-capillary barrier integrity has to be tightly regulated
(1). To that purpose, the continuous capillaries found in the lungs
are very closely packed together. Since the rate of diffusion of O2
and CO2 through the alveolar-capillary barriers is proportional to
the exchange area, but inversely proportional to its thickness, no
excess leakage of liquid should occur in the interstitium and subse-
quently in the alveolar space, since this would dramatically impair
gas exchange between the alveoli and the pulmonary capillaries.
To that purpose, capillary hydrostatic pressure, which is partially
defined by the pulmonary venous pressure and vascular tone,
has to be kept under control, in order to prevent excess fluid
extravasation from the capillaries.
THE ROLE OF ARGINASE DURING LUNG INFLAMMATION: A
COMPLICATED MATTER
Arginase, which converts l-arginine into l-ornithine and urea,
is not only a key enzyme of the hepatic urea cycle, but is also
expressed in extra-hepatic tissues lacking a complete urea cycle.
Whereas cytosolic arginase 1 is the predominant isoform in the
liver, mitochondrial arginase 2 is mainly expressed in extra-hepatic
tissues (2). l-Arginine is not only a substrate for arginase, but can
alternatively be converted to NO and l-citrulline by nitric oxide
synthases (NOS). As such, arginase’s primary biological function
in extra-hepatic organs, such as the lungs, lies mainly in the regu-
lation of NO synthesis, by means of competing with NO synthase
for the common substrate l-arginine.
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FIGURE 1 | Differential role of arginase in small airway epithelial cells,
alveolar macrophages and capillary endothelial cells in the lungs.
Activation of arginase in the small airway epithelial cells (yellow panel) leads
to a reduction in iNOS mRNA and protein expression, as such reducing NO
generation. Since NO suppresses the NFκB response, this culminates in
excessive NFκB activation and inflammation. Alveolar macrophages (green
panel), upon stimulation with mesenchymal stem cell-derived IGF-1 or small
airway epithelial cell-derived CCL2, can convert from a pro-inflammatory
M1 phenotype, characterized by IFN-γ production and high iNOS activity, to
an M2 phenotype, in which IL-4 generation and arginase 1 activity prevail.
Activation of arginase 1 activity in microvascular endothelial cells (blue
panel) leads to a reduction in eNOS-derived NO generation, which in turn
contributes to a loss of barrier function in the capillary compartment.
Increased arginase activity has been reported in several inflam-
matory lung diseases, including asthma, chronic obstructive pul-
monary disease, cystic fibrosis, and pulmonary hypertension. This
suggests a common feature underlying the pathophysiology of
these diseases [reviewed in (3)]. As demonstrated in Figure 1, both
arginase 1 and 2 are constitutively expressed in airway and alveolar
epithelial cells, endothelial cells, and alveolar macrophages in the
lower airways (4, 5). However, the enzyme’s role can be quite dif-
ferent depending on the cell type or the location where its activity
is increased.
PRESERVATION OF ARGINASE ACTIVITY BY
ANTI-INFLAMMATORY THIOREDOXIN 1
The ubiquitously expressed and evolutionary well-conserved
12 kDa protein thioredoxin was initially thought to be primarily
involved in protection against oxidative stress, by means of scav-
enging reactive oxygen species (ROS) through the interaction with
peroxiredoxin and controlling the cellular redox balance (6, 7).
Thioredoxin exists as both a cytoplasmic and an extracellular
form. In contrast to thioredoxin 2, thioredoxin 1 has the capacity to
function as a chaperone for arginase, as such protecting the enzyme
from inhibition by reactive oxygen and nitrogen intermediates and
from denaturation by urea and heat. As such, thioredoxin 1 retains
arginase in a catalytically active state (8).
Thioredoxin not only reduces oxidative and nitrosative stress,
but also suppresses pro-inflammatory cytokine generation (9),
reduces leukocyte-endothelial interactions and preserves arginase
activity, which in turn blunts deleterious inducible NOS (iNOS)
activity. Taken together, all of these activities make thioredoxin a
potent and versatile mediator of inflammation (10, 11). Recombi-
nant human thioredoxin was proposed as a therapeutic candidate
for the treatment of several inflammatory disorders (12).
In the lungs, the induction of thioredoxin is regarded as
an adaptive response against lung inflammation associated with
oxidative stress (13). Recent studies have revealed that exogenously
administered thioredoxin protects the lungs from acute lung injury
induced by influenza virus infection (14). In conclusion, thiore-
doxin 1 has the capacity to preserve arginase activity in pulmonary
cells, as such blunting excessive iNOS activity.
ROLE OF ARGINASE IN ALVEOLAR MACROPHAGES DURING
PULMONARY INFECTION AND INFLAMMATION
In alternatively activated alveolar macrophages of the M2 pheno-
type, arginase activity can limit the consummation of l-arginine
by iNOS, as such suppressing the cytotoxic response by these cells
(Figure 1). Many factors can affect the conversion from the M1 to
the M2 phenotype in these cells.
Following Mycobacterium tuberculosis infection, alveolar
macrophages first become classically (M1) polarized, charac-
terized by an increased expression of IFN-gamma and iNOS
(Figure 1). However, as the inflammation progresses, they decrease
iNOS and IFN-γ expression, but increase IL-4 generation and
arginase 1 activity, indicating M2 polarization (15). By contrast, M.
tuberculosis-induced granuloma-associated macrophages remain
M1-polarized throughout the entire process. Azithromycin treat-
ment was shown to have the potential to induce M2 polarization of
alveolar macrophages, e.g., in a Pseudomonas aeruginosa infection
model (16).
The NO-generating capacity and arginase activity of alveo-
lar macrophages also seems to affect susceptibility to infection
with Chlamydia. Indeed, C57BL/6 mice develop severe pneumonia
and poor immunity against Chlamydia after moderate respiratory
infection, whereas BALB/c mice are protected from the disease and
develop a vigorous Th1 response. Infected C57BL/6 macrophages
release more iNOS-derived NO than BALB/c macrophages and
express lower mRNA concentrations of arginase 2. Reduction
of NO production upon incomplete iNOS inhibition abolishes
susceptibility of C57BL/6 mice to Chlamydia-induced disease.
Thus, the quantity of NO released by infected macrophages seems
to define pathogenic versus protective macrophage responses to
chlamydial infection (17).
In rat alveolar macrophages,bacterial lipopolysaccharide (LPS),
released upon antibiotic treatment, was shown to increase both
arginase 1 and 2 expression, an effect which could be blunted
by glucocorticoids (5). It is important to note that arginase in
alveolar macrophages not only contributes to impairment of NO
generation, but it can also mediate airway remodeling, as detected
in asthma, cystic fibrosis, and COPD, through the increased pro-
duction of l-proline, a precursor of collagen, and the polyamines
putrescine, spermidine, and spermine from l-ornithine (18).
The role of arginase in alveolar macrophages in LPS-
induced acute lung injury remains controversial, since a recent
study reported that mesenchymal stem cell-conditioned medium
mediates the resolution of LPS-induced acute lung injury,
by attenuating lung inflammation and promoting a wound
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healing/anti-inflammatory M2 macrophage phenotype, charac-
terized by increased arginase 1 activity, at least partially in an
insulin growth factor 1 (IGF-1)-dependent manner (19).
ROLE OF ARGINASE IN SMALL AIRWAY AND ALVEOLAR
EPITHELIAL CELLS
From the previous paragraph, it is noteworthy that the switch of
alveolar macrophages from the M1 to the M2 phenotype can be
mediated by other cell types in the lower airways. This is not only
the case for mesenchymal stem cells, but also for airway epithelial
cells. Indeed, supernatants from chitin-treated airway epithelial
cells were shown to induce alternative M2 activation of alveolar
macrophages in vivo, by means of a CCL2 chemokine-dependent
mechanism [Figure 1; (20)].
Moreover, TGF-β2 was shown to impact cytokine-induced NO
production in primary small airway epithelial cells, by enhancing
total arginase activity and reducing iNOS mRNA and protein lev-
els, through a Rho kinase-dependent pathway (21). In a different
study, reduction of arginase activity was shown to enhance the
cellular content of NO and S-nitrosated proteins in a mouse type
II alveolar epithelial cell line (22). As a consequence, TNF- or LPS-
stimulated NF-κB DNA binding and transcriptional activity was
decreased, in combination with an enhanced S-nitrosation of p50.
The NOS inhibitor N-omega-nitro-l-arginine methyl ester (L-
NAME) reversed the effects of arginase inhibition on NF-κB, sug-
gesting a causal role for NO in the attenuation of NF-κB induced
by arginase suppression. Conversely, overexpression of arginase
1 decreased cellular S-nitrosothiol content, enhanced IκB kinase
activity and NF-κB DNA binding and decreased S-nitrosation
of p50.
These results point to a regulatory mechanism wherein NF-κB
is controlled through arginase-dependent regulation of NO lev-
els, which may impact on chronic inflammatory diseases that are
accompanied by NF-κB activation and upregulation of arginases
(22, 23).
REGULATION OF CAPILLARY ENDOTHELIAL PERMEABILITY
Endothelial cells form confluent monolayers on the surface
of the inner wall of blood vessels. One of their major func-
tions is therefore the separation of blood from underlying tis-
sues, allowing only tightly controlled passage of macromolecules
and cells. In the lower airways, where the actual gas exchange
between the alveoli and the capillaries only efficiently occurs
when barriers are tight (1), confluence is crucial. The adher-
ence of endothelial cells is formed by transmembrane adhesion
proteins, which mediate homophilic adhesion and junctional
structures.
The transmembrane proteins are linked to specific intracellu-
lar partners, which mediate anchorage to the actin cytoskeleton
and, as a consequence, stabilize junctions. The changes in the
components of the EC cytoskeleton are of critical importance
in the determination of the actual shape of the cell. The actin
filaments and the phosphorylation/dephosphorylation-controlled
actomyosin interactions are dramatically involved in the increase
of the vascular permeability. Phosphorylation/dephosphorylation
events of cytoskeletal/cytoskeleton-associated proteins also have a
regulatory role in endothelial barrier regulation. Ca2+, calmod-
ulin, and myosin light chain kinase (MLCK) were shown to
be required components for endothelial cell retraction, whereas
myosin phosphatase restores endothelial relaxation (24).
Two main signaling pathways regulate the barrier function, via
the inhibition of myosin phosphatase. One of them is the vasoac-
tive agent-induced Rho pathway, which increases the endothelial
permeability. Rho Kinase (ROCK) may increase myosin light chain
(MLC) phosphorylation indirectly by means of inducing myosin
phosphatase inactivation, accumulation of diphospho-MLC, and
cell contraction. Another pathway involves the Protein Kinase C
(PKC)-potentiated inhibitory protein of 17 kDa (CPI-17), which
may also affect isolated protein phosphatase 1c (PP1c) or the
holoenzyme form of myosin phosphatase, without dissociating
its subunits (25, 26).
External factors, such as certain G+ bacterial toxins (e.g., pneu-
molysin and listeriolysin) or pro-inflammatory cytokines, such
as TNF, can induce increases in Ca2+-influx in endothelial cells,
which can affect the microtubular network dynamics. Increases
in intracellular Ca2+ can induce disassembly of microtubules
(27). The microtubule population in endothelial cells is hetero-
geneous and can be divided into (1) stable, modified (acetylated),
and (2) dynamic microtubules, with the former ones being more
stable and thus more resistant to the effects of external fac-
tors. It is possible that under conditions compromising vascular
endothelial integrity, the stable microtubules may confer stability
to the endothelial microtubule network (28). Depolymerization
of microtubules can in turn cause disassembly of adherens junc-
tion proteins with which they associate, such as VE-cadherin, thus
increasing permeability (29).
RESTORING CAPILLARY BARRIER FUNCTION IN
PNEUMONIA: A THERAPEUTIC PRIORITY
Childhood pneumonia is the leading single cause of mortality
worldwide in children aged less than 5 years (30). Moreover, over
four million people develop pneumonia each year in the United
States, with over a half a million of them being admitted to a hos-
pital for treatment. Community-acquired pneumonia (CAP) rep-
resents a major cause of morbidity and mortality in mainly elderly
patients (31, 32). The leading bacterial cause is the Gram-positive
bacterium Streptococcus pneumonia (pneumococcus), being iden-
tified in 30–50% of pneumonia cases. The fatality rate associated
with Streptococcus pneumoniae, the main etiological agent of severe
pneumonia, still approximates 20%, despite the use of potent
antibiotics and aggressive intensive-care support (30, 32).
Permeability edema, associated with severe pneumonia, acute
lung injury, and the acute respiratory distress syndrome (ARDS),
is characterized by a dysfunction of the alveolar-capillary bar-
riers, leading to an infiltration of, e.g., neutrophils and factors
contained in the blood into the alveoli. In severe pneumonia,
this condition, characterized by capillary endothelial hyperperme-
ability, can occur days after initiation of antibiotic therapy, thus
when tissues are already sterile. Permeability edema in pneumo-
coccal pneumonia correlates with the presence of the bacterial
virulence factor pneumolysin (33, 34), a cytoplasmic hemolytic
protein released during bacterial autolysis or upon treatment with
β-lactam antibiotics (35). Pneumolysin-induced acute lung injury
was suggested to result from direct pneumotoxic effects on the
alveolar-capillary barrier, rather than from resident or recruited
phagocytic cells (36).
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Intravascular pneumolysin was shown to cause a significant
dose-dependent increase in pulmonary vascular resistance and in
lung microvascular permeability. Upon binding of pneumolysin to
cholesterol in cell membranes, oligomerization, and pore forma-
tion occur, which causes increased intracellular Ca2+ levels (37),
the initial pivotal signal preceding pathways leading to endothe-
lial cell contraction (38), including MLC-dependent mechanisms
and microtubule rearrangement. RhoA and Rho-associated kinase
may directly catalyze MLC phosphorylation or act indirectly via
inactivation of myosin phosphatase to induce cell contraction
and endothelial barrier disruption. In turn, endothelial barrier
enhancement is associated with Rac 1-mediated formation of
F-actin, increased association of focal adhesion proteins, and
enlargement of intercellular adherens junctions. Thus, a precise
balance between RhoA- and Rac1-mediated signaling is essential
for endothelial barrier regulation.
The Ca2+-dependent PKC isoform, PKC-α, was suggested to
play a critical role in initiating endothelial cell contraction and
disassembly of VE-cadherin junctions (39–41). The NADPH oxi-
dases, Nox2 and Nox4, are major sources of ROS in endothelial
cells and are implicated in redox-sensitive signaling pathways that
influence endothelial cytoskeletal organization and permeabil-
ity (42, 43). Apart from inducing RhoA activation (41), PKC-α
activation was also recently shown to upregulate Nox 4 mRNA
expression in human endothelial cells (44).
In view of its crucial role in bacterial virulence and its pro-
found effects on the immune system of the host, pneumolysin can
be considered as a model toxin for G+ infection-associated acute
lung injury and permeability edema. Since no standard therapy
is currently available to treat the pulmonary permeability edema
associated with severe pneumonia, the need for novel substances
that can improve oxygenation in these patients, by means of barrier
restoration is thus very important.
AN IMPORTANT ROLE FOR ARGINASE 1 IN
PNEUMOLYSIN-MEDIATED CAPILLARY LEAK
In the larger blood vessels, impaired vasorelaxation capacity can be
caused by dysfunctional endothelial nitric oxide synthase (eNOS)-
dependent NO generation and increased eNOS-dependent ROS
production. Moreover, in acute lung injury, the nitrating agent
peroxynitrite, which can be formed by the reaction between ROS
and NO in severe pathophysiological situations, can further deteri-
orate the vascular dysfunction (45). Endothelial NOS dysfunction
in large vessel endothelial cells can be induced upon arginase 1
activation (46, 47). Although it is generally recognized that NO
is a crucial regulator of vessel vasodilation, its role in the capil-
laries is less well documented, apart from its anti-adhesive and
anti-aggregatory effects on platelets (48).
Maintenance of the endothelial barrier requires a basal level of
NO, regulated by eNOS (49). Both the lack of NO and high NO
levels destabilize inter-endothelial junctions (50–52). Availability
of the semi-essential amino acid l-arginine is required for eNOS
activity and NO production and is essential for vascular integrity
and function. Recent studies have indicated that increased activity
and/or overexpression of the enzyme arginase, which is thought
to be dependent on RhoA activation, may play an important role
in the availability of l-arginine and thus in the pathogenesis of
vascular dysfunction (46, 53). Both arginase 1 and 2 have been
found in endothelial cells, with arginase 1 being the dominant
isoform. Arginase competes with eNOS for their common sub-
strate, l-arginine, thus reducing the NO-generating capacity of
the enzyme. Endothelial NOS catalyzes the two step conversion of
substrate l-arginine into NO and utilizes electrons from NADPH
to reduce molecular oxygen followed by oxidation of the guanidino
N group of arginine to form NO, l-citrulline, and water (54).
It is this repeated activation of molecular oxygen that presents
the opportunity for enzymatic missteps and superoxide produc-
tion from eNOS, in the presence of reduced l-arginine availability,
a process that has been termed “eNOS uncoupling” (54, 55). All of
these events will culminate in endothelial hyperpermeability.
Our recent studies have shown that treatment of human lung
microvascular endothelial cells with a sublytic concentration of
pneumolysin, within 2 h significantly increases both arginase 1 and
2 expression, as well as arginase activity (56). This is accompanied
by a significant reduction in basal NO generation and hyperper-
meability in these cells. Both the barrier function and the NO
generation can be partially restored upon treating the cells with the
arginase inhibitor (S)-(2-boronoethyl)-l-cysteine (BEC) or with
the PKC-α inhibitor Ro32-4032 in vitro. PKC-α signals RhoA acti-
vation (57), which in turn is involved in the activation of arginase
activity in endothelial cells (58, 59).
Moreover, both the arginase inhibitor BEC and the PKC-α
inhibitor Ro32-4032 can blunt pneumolysin-induced endothe-
lial hyperpermeability in HL-MVEC in vitro. These results are
substantiated in vivo, since arginase 1+/−/arginase 2−/−, but not
arginase 1+/+/arginase 2−/− mice (60) are significantly protected
from pneumolysin-induced capillary leak (56).
Taken together, these results demonstrate an important role
for arginase 1 in pneumolysin-induced barrier dysfunction in
HL-MVEC.
MANIPULATING ARGINASE ACTIVITY IN ACUTE LUNG
INJURY: HANDLE WITH CARE
The previous paragraph points toward a potential therapeutic
potential for arginase inhibitors in the treatment of capillary leak
associated with acute lung injury, ARDS, and severe pneumonia.
However, as previously discussed, the important role of arginase
in the M2 phenotype of alveolar macrophages, which can, e.g.,
promote clearance of LPS-induced edema inflammation, makes a
general inhibition of arginase activity in the lungs during infection
problematic. Moreover, direct arginase inhibitors block arginase
activity not only in the endothelium but also in other tissues,
such as the liver, where its activity is needed in the urea cycle.
As such, whereas arginase inhibition in capillary endothelial cells
might increase their barrier function, it can potentially also lead
to the conversion of alveolar macrophages from the protective
M2 to the deleterious inflammatory M1 phenotype, the latter of
which is characterized by excessive iNOS-mediated NO genera-
tion. Moreover, arginase inhibition in type II alveolar epithelial
cells can also cause activation of iNOS and thus excessive NO
production, shown to blunt the open probability of the epithelial
sodium channel, crucial for alveolar liquid clearance during acute
lung injury (61, 62). Furthermore, because arginase is involved
in macrophage-mediated anti-bacterial responses and in wound
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repair (63), it is possible that substances inhibiting its activation,
although conferring resistance to pneumolysin-mediated vascular
leak, can interfere with macrophage-mediated innate immunity to
pneumococci and wound healing. The same holds true for PKC-α
proposed to be important for T-cell proliferation and IFN-γ pro-
duction (64), and as such can be involved in anti-bacterial defense
mechanisms, making that direct PKC-α inhibitors potentially can
have negative effects on adaptive immunity.
Therefore, alternative substances interfering with the activation
of arginase 1, rather than with its activity per se, preferentially in the
endothelium, should be identified and investigated more in detail.
Although it is generally assumed that cytokines solely exert
their activities upon activating their respective receptors, this does
not seem to be true in the case of TNF. Apart from its receptor
binding sites, which mediate a plethora of biological activities,
ranging from apoptosis to inflammation and proliferation (65,
66), TNF exerts a lectin-like activity, permitting its binding to
glycoproteins such as uromodulin, with a K D= 10−10 M (67) uro-
modulin is a glycoform of Tamm–Horsfall protein, found in the
loops of Henle of pregnant women, which was shown to bind the
pro-inflammatory cytokines, IL-1β, IL-2, and TNF, proposed as
a mechanism to clear excessive levels of these cytokines from the
circulation during pregnancy (67, 68).
Since uromodulin-bound TNF was still able to exert cyto-
toxic effects in L929 fibrosarcoma cells, it was proposed that the
lectin-like domain of TNF has to be spatially distinct from its
receptor binding sites. Specific oligosaccharides, such as N,N ′-
diacetylchitobiose, as well as branched trimannoses, which are
known to bind to the lectin-like domain of TNF, are able to
inhibit the necrotic activity of TNF in African trypanosomes,
but not the cytotoxic activity of TNF in L929 cells. Moreover,
lectins with a similar oligosaccharide specificity as TNF, such as
Urtica Dioica Agglutinin, but not those with a different speci-
ficity,block the trypanolytic effect of TNF (69). Molecular graphics
comparisons of tertiary structures of TNF (trypanolytic) and the
highly homologous lymphotoxin-α (non-trypanolytic), lead us to
propose a dissimilar structure that could be responsible for the
lectin-like activity. This structure, which is present at the Tip of the
TNF molecule can be mimicked by a circular 17 amino acid pep-
tide, which we called the TIP peptide. Antibodies to this peptide
were able to inhibit the trypanolytic activity and moreover, the TIP
peptide itself was shown to exert trypanolytic activity (69). Three
amino acids, i.e., one threonine and two glutamic acids were shown
to be crucial for this activity.
Our recent data have demonstrated that the TIP peptide
inhibits pneumolysin-induced PKC-α and arginase activation and
restores basal NO generation in human microvascular endothe-
lial cells monolayers. The peptide moreover significantly protects
from pneumolysin-induced capillary leak in vivo (56). Since the
TIP peptide also activates lung liquid clearance upon stimulating
epithelial sodium channel function, the latter of which is impaired
by pneumolysin (70), it is further being investigated as an alter-
native to inhibitors of arginase and PKC-α in the treatment of
permeability edema. As such, the peptide is being tested in two
phase 2a clinical trials in patients with acute lung injury.
GENERAL CONCLUSION
Recent studies have revealed a complex role for arginase dur-
ing acute lung injury. On the one hand, activation of arginase
1 in alveolar macrophages, as can be induced by airway epithe-
lial cells or mesenchymal stem cells, promotes the protective M2
phenotype in these cells, reducing deleterious iNOS activity. By
sharp contrast, an increase in arginase 1 activity in pulmonary
microvascular endothelial cells, as can be induced by bacterial tox-
ins, can mediate capillary endothelial hyperpermeability, by means
of reducing basal eNOS-dependent NO generation, crucial for the
generation of basal barrier function. These findings thus clearly
document the difficulty to develop therapies interfering directly
with arginase activity during acute lung injury. As such, targeting
arginase in specific cell types in the lungs, using, e.g., genetically
modified mice with inducible constructs could lead to a better
understanding of this complex area.
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